{"entity":{"id":"nct02346747","kind":"trial","name":"A Trial of Vigil for Participants With Ovarian Cancer","aka":["VITAL"],"tldr":"A phase 2 trial of Vigil in ovarian cancer, run by Gradalis, Inc., active and no longer recruiting.","summary":"A Trial of Vigil for Participants With Ovarian Cancer is a phase 2 interventional study registered as NCT02346747 by Gradalis, Inc., with 92 participants enrolled, started 2015-02 and due to reach its primary completion in 2028-12. Interventions recorded: Vigil.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT02346747","url":"https://clinicaltrials.gov/study/NCT02346747"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["ovarian"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT02346747","phase":"2","setting":"A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of Vigil Engineered Autologous Tumor Cell Immunotherapy in Subjects With Stage IIIb-IV Ovarian Cancer in Clinical Complete Response Following Surgery and Primary Chemotherapy","sponsor":"Gradalis, Inc.","participation":[{"nct":"NCT02346747","source":"https://clinicaltrials.gov/study/NCT02346747","fetchedAt":"2026-10-07T16:52:43.505Z","studySha256":"708c19cbf6a25cc3d115ba21a3c6695e19d96293aa70bffa18983eb0c7d189ba","overallStatus":"ACTIVE_NOT_RECRUITING","lastUpdatePosted":"2025-10-29","leadSponsor":"Gradalis, Inc.","collaboratorCount":0,"minimumAge":"18 Years","sex":"FEMALE","healthyVolunteers":false,"hasEligibility":true,"enrolment":92,"enrolmentType":"ACTUAL","siteCount":26,"recruitingSiteCount":0,"countries":["United States"]}],"started":"2015-02","startedType":"actual","enrolled":92,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct02346747/","neighbours":{"cancer":[{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/"}]}}